{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:04:01Z","timestamp":1784891041434,"version":"3.55.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R\/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study investigated the use of tocilizumab for managing CAR-T-related CRS in 45 R\/R B-ALL patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. Additionally, 10 patients showed decreased cytokine levels.Importantly, tocilizumab did not impair CAR-T cell expansion or efficacy, nor did it increase the incidence of adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These findings suggest that tocilizumab may be an effective and safe strategy for mitigating CAR-T-related CRS in R\/R B-ALL patients, potentially improving patient outcomes and survival.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1530623","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T07:08:03Z","timestamp":1741936083000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia"],"prefix":"10.3389","volume":"16","author":[{"given":"Qianyi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengjiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yedi","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanxia","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuicui","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianle","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet (London England)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet (London England)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"New Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet (London England)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/cam4.v10.3","article-title":"Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed\/refractory large B-cell lymphoma in China","volume":"10","author":"Ying","year":"2021","journal-title":"Cancer Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet (London England)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann oncology: Off J Eur Soc Med Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","author":"Neelapu","year":"2019","journal-title":"Hematological Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.02.012","article-title":"Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery","volume":"26","author":"Gutgarts","year":"2020","journal-title":"Biol Blood marrow transplantation: J Am Soc Blood Marrow Transplantation"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.745320","article-title":"Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-hodgkin lymphoma","volume":"12","author":"Caimi","year":"2021","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: A prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J Clin oncology: Off J Am Soc Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.03.004","article-title":"Early time-to-tocilizumab after B cell maturation antigen-directed chimeric antigen receptor T cell therapy in myeloma","volume":"27","author":"Banerjee","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.914959","article-title":"Timing of tocilizumab administration under the guidance of IL-6 in CAR-T therapy for R\/R acute lymphoblastic leukemia","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25108","article-title":"Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"93","author":"Cao","year":"2018","journal-title":"Am J hematology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1139559","article-title":"Low-dose administration of prednisone has a good effect on the treatment of prolonged hematologic toxicity post-CD19 CAR-T cell therapy","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1097\/HS9.0000000000000191","article-title":"In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy","volume":"3","author":"Garcia Borrega","year":"2019","journal-title":"HemaSphere"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02941-4","article-title":"CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease","volume":"70","author":"Lu","year":"2021","journal-title":"Cancer immunology immunotherapy: CII"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2021.399","article-title":"Outcomes of anti-CD19 CAR-T treatment of pediatric B-ALL with bone marrow and extramedullary relapse","volume":"54","author":"Wan","year":"2022","journal-title":"Cancer Res Treat"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.v94.S1","article-title":"Toxicities of CD19 CAR-T cell immunotherapy","volume":"94","author":"Hirayama","year":"2019","journal-title":"Am J Hematol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41392-020-00256-x","article-title":"The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma","volume":"5","author":"Wei","year":"2020","journal-title":"Signal transduction targeted Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1629904","article-title":"Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome","volume":"15","author":"Kotch","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41408-024-01048-0","article-title":"Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"14","author":"Costa","year":"2024","journal-title":"Blood Cancer J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.08.018","article-title":"Tocilizumab prophylaxis following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00207-7","article-title":"Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients","volume":"2","author":"Biasco","year":"2021","journal-title":"Nat cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.5414\/CP201549","article-title":"Thorough QT\/QTc study of tocilizumab after single-dose administration at therapeutic and supratherapeutic doses in healthy subjects","volume":"49","author":"Grange","year":"2011","journal-title":"Int J Clin Pharmacol Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-014-8590-4","article-title":"Tocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: case series and review of literature","volume":"61","author":"Shovman","year":"2015","journal-title":"Immunologic Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic Malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer discovery"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v130.15","article-title":"Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia","volume":"130","author":"Wang","year":"2024","journal-title":"Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J haematology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3390\/biom13020382","article-title":"Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome","volume":"13","author":"Lakomy","year":"2023","journal-title":"Biomolecules"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2021.09.002","article-title":"Chinese expert consensus on prevention and treatment of immunotherapeutic and molecular targeted agents-related infections in patients with hematological Malignancies (2021 version)","volume":"42","author":"Liu","year":"2021","journal-title":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann oncology: Off J Eur Soc Med Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003379","article-title":"Recommendations for the timing, dosage, and usage of corticosteroids during cytokine release syndrome (CRS) caused by chimeric antigen receptor (CAR)-T cell therapy for hematologic Malignancies","volume":"137","author":"Tu","year":"2024","journal-title":"Chin Med J"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1530623\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T07:08:07Z","timestamp":1741936087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1530623\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2025.1530623"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1530623","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"article-number":"1530623"}}